Entera Bio Ltd. entered into a Securities Purchase Agreement on July 26, 2026, closing on July 28, 2026, to raise approximately $275.0 million in a private placement. The company issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants at a price of $2.04 per share. Proceeds will fund the Phase 3 registrational study of EB613 for postmenopausal osteoporosis and general working capital. BVF Partners L.P. received the right to designate two board directors, contingent on maintaining specific ownership thresholds. The company agreed to appoint two new independent directors by the 2027 annual meeting, triggering the resignation of current directors Haya Taitel and Yonatan Malca. Entera Bio Ltd. operates in the biotechnology industry, developing therapies for metabolic and bone diseases.